Program NVGCT spring symposium 2017
Thursday March 16
09.30 Coffee and Registration
10.00 Opening
Gerard Wagemaker, President of the NVGCT
10.05 Session 1: Oncolytic Immunotherapy I
Chair: Bernadette van den Hoogen
10.05-10.40 Inv 1: Akseli Hemminki
University of Helsinki and TILT Biotherapeutics, Helsinki, Finland
Oncolytic immunotherapy with replicating adenoviruses: what has human data taught us?
10.40-11.00 Oral 1: Marta Lopez Gonzalez
VU University medical center, Amsterdam
Enhanced suppressive effects of melanoma cells on dendritic cell differentiation upon infection with an oncolytic adenovirus
11.00-11.20 Oral 2: Ioanna Milenova
ORCA Therapeutics, Amsterdam
Enhancing the antitumor immune response by combined treatment with immune-stimulatory factors and an oncolytic adenovirus in a melanoma model
11.20-11.55 Inv 2: Martine Lamfers
Erasmus University Medical Center, Rotterdam
Oncolytic adenovirus for treatment of malignant glioma: from virotherapy to immuno-virotherapy
12.00 Lunch
13.00 Keynote Lecture Oncolytic Immunotherapy
Chair: Victor van Beusechem
Kevin Harrington
The Institute of Cancer Research, London, UK
Oncolytic Viruses Are Potent Anti-Cancer Agents When Used in Combination with Targeted Therapies
13.50 Session 2: Therapeutic cellular products
Chair: Enrico Mastrobattista
13.50-14.25 Inv 3: Ton Schumacher
Kite Pharma and The Netherlands Cancer Institute, Amsterdam
Generation of tumor-specific T cell immunity in human cancer
14.25-15.00 Inv 4: Zsolt Sebestyen
University Medical Center Utrecht
Reality check on gdT cells: from bench to bedside
15.00 Tea Break
13.50 Session 2 (continued): Therapeutic cellular products
Chair: Enrico Mastrobattista
15.20-15.40 Oral 3: Patrick Burger
Sanquin Research, Amsterdam
Large scale culture and differentiation of erythroblasts from PBMC and iPSC
15.40-16.00 Oral 4: Miranda Meeuwsen
Leiden University Medical Center
Identification of high affinity B-cell malignancy specific T-cell receptors
16.00-16.20 Oral 5: Amiet Chhatta
Leiden University Medical Center
Generation of Functional Human Thymic Epithelial Cells by Directed Differentiation of Induced Pluripotent Stem Cells
16.20 NVGCT General Assembly (ALV)
16.45 Brainstorm NVGCT Future Directions
17.30 Networking and Drinks
18.30 Dinner
20.30 Social event (Pubquiz)
Quiz-Master: Rob Collin
Friday March 17
9.00 Session 3: Gene Therapy for Inherited and Acquired Diseases
Chair: Rob Collin
9.00-9.20 Oral 6: Xiaoxia Shi
Academic Medical Center, Amsterdam
Insertion of a liver-specific promoter in an rSV40 vector results in improved expression of therapeutic genes in hepatoma cell lines
9.20-9.40 Oral 7: Sabine van der Sanden
Erasmus University Medical Center, Rotterdam
Development of an improved ND4 gene therapy for Leber Hereditary Optic Neuropathy by packaging adeno-associated virus in exosomes
9.40-10.00 Oral 8: Alejandro Garanto
Radboud University Medical Center, Nijmegen
Expanding the use of antisense oligonucleotide-based therapeutic approaches for inherited retinal dystrophies
10.00-10.20 Oral 9: Sem Aronson
Academic Medical Center, Amsterdam
Loss of AAV-mediated therapeutic correction in Ugt1a1-deficient rats treated at young age
10.20-10.40 Oral 10: E.C.A. Nyns
Leiden University Medical Center
Light pulse terminates ventricular tachyarrhythmias in the adult rat heart upon optogenetic modification
10.40 Coffee Break
11.00 Session 5: Cellular Immunotherapy
Chair: [Toos Daemen]
11.00-11.35 Inv 5: Jolanda de Vries
Radboud University Medical Center, Nijmegen
Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome
11.35-12.10 Inv 6: Cor Lamers
Erasmus University Medical Center, Rotterdam
Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer
12.10 NVGCT Greiner Bio-One Award
Chair: Victor van Beusechem
Award delivery, Jury report and Award Lecture
12.45 Lunch
13.45 Keynote Lecture Cellular Immunotherapy
Chair: Tanja de Gruijl
David Gilham
Celyad S.A., Mont Saint Guibert, Belgium
CAR T Cell Therapy for Cancer: Moving Beyond CD19
14.35 Competent Authority Update
Chair: Rob Hoeben
Rik Bleijs
GMO Office, Bilthoven
Update on Gene Therapy Regulations in Europe
14.45 Session 4: Oncolytic Immunotherapy II
Chair: Rob Hoeben
14.45-15.05 Oral 11: Victor Cervera-Carrascon
TILT Biotherapeutics, Helsinki, Finland
Remodeling the tumor microenvironment with oncolytic viruses in order to enable immune checkpoint blockade and adoptive cell therapy
15.05-15.25 Oral 12: Tereza Brachtlova
VU University medical center, Amsterdam
Determination of the Optimal Format for Functional Expression of microRNA from the Adenovirus Genome
15.25-15.45 Oral 13: Joao Santos
TILT Biotherapeutics, Helsinki, Finland
Local IL-2 production by a tumor-specific adenoviral vector rather than systemic IL-2 postconditioning results in safety and efficacy gains in adoptive cell therapy
15.45-16.05 Oral 14: Vera Kemp
Leiden University Medical Center
Oncolytic reovirus infection is facilitated by the autophagic machinery
16.05 Closure
Gerard Wagemaker, President of the NVGCT